Discover 920 paid clinical trials in Portland, Oregon. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 920
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
for
Lymphoma, Large B-Cell, Diffuse
Location: Portland OR, Vancouver WA, Post Falls ID,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06890884
Phase2, Recruiting
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
for
Lung Neoplasm Malignant
Location: Portland OR, Chicago IL, Clermont FL
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07286149
Phase1, Phase2, Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Location: Portland OR, Los Angeles CA, Duarte CA, San Diego CA,
Sponsor: SystImmune Inc.
Sex: All
Age: 18+
Code: NCT06293898
Phase1, Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Portland OR, Bend OR, Yakima WA, Issaquah WA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04269902
Phase3, Recruiting
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
for
Acral Lentiginous Melanoma,
Location: Portland OR, Clackamas OR, Vancouver WA, Oregon City OR,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT04511013
Phase2, Recruiting
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
for
Metastatic Nasopharyngeal Carcinoma,
Location: Portland OR, Seattle WA, Post Falls ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06029270
Phase2, Recruiting
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
for
Intracranial Meningioma, Recurrent Meningioma,
Location: Portland OR, Clackamas OR, Vancouver WA, Oregon City OR,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT02523014
Phase2, Recruiting
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
for
Metastatic Small Intestinal Adenocarcinoma,
Location: Portland OR, Clackamas OR, Vancouver WA, Oregon City OR,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT04205968
Phase2, Recruiting
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
for
Mantle Cell Lymphoma
Location: Portland OR, Oregon City OR, Newberg OR, Issaquah WA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 60+
Code: NCT05976763
Phase3, Recruiting
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
for
Smoldering Plasma Cell Myeloma
Location: Portland OR, Clackamas OR, Vancouver WA, Oregon City OR,
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All
Age: 18+
Code: NCT03937635
Phase3, Recruiting
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Location: Portland OR, Olympia WA, Puyallup WA, Bonney Lake WA,
Sponsor: American Society of Clinical Oncology
Sex: All
Age: 12+
Code: NCT02693535
Phase2, Recruiting
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
for
Locoregional Recurrence,
Location: Portland OR, Phoenix AZ, Albuquerque NM, Omaha NE,
Sponsor: Oana Danciu
Sex: All
Age: 18+
Code: NCT05467891
Phase2, Recruiting
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: Portland OR, Oregon City OR, Ontario OR, Post Falls ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06589804
Phase3, Recruiting
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer